RBC keeps AUD 21.00 target for Telix Pharmaceuticals stock

Published on 10/24/2026 at 18:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached US$245.00 million, up 19.00 percent year over year. Telix Pharmaceuticals stock costs EUR 8.14 on October 24, 2026.

Analyst target and reporting date

RBC reaffirmed an AUD 21.00 target for Telix on October 21, 2026.
Third-quarter revenue reached US$245.00 million, up 19.00 percent year over year.
Telix stock costs EUR 8.14 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, while the ASX closed at AUD 13.19 on October 23.
Telix expects its shareholder meeting on December 1, 2026.

Telix, AU000000TLX2, Illustration mit AI erstellt.

RBC reaffirmed its AUD 21.00 price target for Telix Pharmaceuticals on October 21, 2026, according to IT Boltwise. Telix stock was trading at EUR 8.14 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Revenue grows in the third quarter

GlobeNewswire reported on October 21, 2026 that Telix generated US$245.00 million of group revenue in the quarter ended September 30, 2026. That was 19.00 percent above the US$206.00 million reported for the third quarter of 2025, but 1.00 percent below the US$247.00 million recorded in the second quarter of 2026.

Precision Medicine revenue rose 30.00 percent year over year to US$201.00 million, while Telix Manufacturing Solutions revenue fell 6.00 percent to US$44.00 million. The mix puts the imaging business ahead of manufacturing in the latest quarterly update.

Telix remains below its yearly high

Telix closed at AUD 13.19 on the ASX on October 23, 2026, down 3.44 percent from AUD 13.66. Its 52-week ASX range was AUD 8.26 to AUD 18.22, while volume reached 3,151,131 shares. The current Australian-dollar price was 27.61 percent below the 52-week high, calculated from AUD 13.19 and AUD 18.22.

Valuation meets a December date

Telix had a market capitalization of AUD 4.5 billion and a price-to-earnings ratio of 102.89 on October 23, 2026. The company expects a general meeting of shareholders on December 1, 2026, where investors are scheduled to consider matters related to the ITM transaction, as reported by StockTitan.

RBC's AUD 21.00 target stands 59.21 percent above the AUD 13.19 ASX price cited on October 23, 2026. That comparison uses the same Australian-dollar basis and highlights the gap between the analyst view and the latest home-market quotation.

Price and outlook

Telix combines commercial radiopharmaceutical products with a development pipeline spanning cancer imaging and targeted therapies. The third-quarter update also said fiscal year 2026 revenue and other income should exceed US$1.0 billion, with revenue tracking toward the upper end of the US$950.00 million to US$970.00 million range.

Telix stock costs EUR 8.14 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST; the ASX closed at AUD 13.19 on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Telix stock.